No Data
No Data
We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely
LENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ Therapeutics Analyst Ratings
H.C. Wainwright Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $38
Leerink Partners Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Announces Target Price $36
LENZ Therapeutics | 10-Q: Q3 2024 Earnings Report
EZ_money : thanks
Stock_Drift OP EZ_money : YW.
EZ_money : JET.AI looks like it bottomed out
Lostboy98 : Is it upstairs or downstairs?
Stock_Drift OP EZ_money : Agreed. Just sits there.
View more comments...